Tevogen Bio Holdings Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$26.1M | -$53.6M | -$8.8M | — | — |
| Operating expenses | $26.1M | $53.6M | $8.8M | — | — |
| Cash from operations | -$12.3M | -$12.0M | -$8.2M | -$215,395 | — |
| Capital expenditure | $64,439 | — | $133,000 | — | — |
| Free cash flow | -$12.4M | — | -$8.3M | — | — |
| Share repurchases | — | — | $343.0M | — | — |
| Total assets | $4.4M | $3.5M | $5.5M | $357.1M | $352.9M |
| Total liabilities | $12.6M | $10.1M | $99.9M | $15.1M | $15.2M |
Shares outstanding 4.2M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.